Pattern of Drug Resistance Among Patients Presenting with Relapse of Pulmonary Tuberculosis
DOI:
https://doi.org/10.51253/pafmj.v74i2.7772Keywords:
Antitubercular Agents, Drug Resistance, Drug Susceptibility Testing, Extensively Drug-resistant Tuberculosis, Multidrug-resistant TuberculosisAbstract
Objective: To assess the patterns of drug resistance (DR) among patients previously treated for pulmonary tuberculosis (TB).
Study Design: Cross-sectional study.
Place and Duration of Study: Department of Medicine, Pak-Emirates Military Hospital, Rawalpindi Pakistan, from Jul 2020 to Mar 2021.
Methodology: Patients with previously treated pulmonary TB were included, based on their clinical history and characteristic chest X-ray findings. Patients were evaluated through an examination of sputum and/or bronchoalveolar washings for acidfast bacilli (AFB), Mycobacterium TB-GeneXpert/RIF (Rifampicin) assay, and mycobacterial culture with drug susceptibility testing (DST). Patients with resistance to any anti-TB drug were classified as cases of DR-TB, and a pattern of drug resistance was documented.
Results: One hundred twenty patients were identified as having been previously treated for TB. DST demonstrated DR-TB among 38(31.7%) cases, while isoniazid (INH) resistance was the most commonly reported problem in 29(24.2%) cases. Up to 26(21.6%) relapsing cases were resistant to Rifampicin (RFM). Moreover, 15(12.5%) instances of resistance against second-line anti-TB drugs (fluoroquinolones and aminoglycosides) were documented. Multidrug-resistant TB (MDR-TB) was the most prevalent resistance pattern in 20(16.7%) cases, followed by mono-drug-resistant TB in 7(5.8%) and extensively resistant TB (XDR-TB) in 2(1.6%) cases. No definitive resistance pattern was evident among 9(7.5%) cases.
Conclusion: MDR-TB constitutes a major barrier in the line of TB eradication in Pakistan. Strict compliance with anti-TB protocols, along with a universal application of DST, can minimize the overall prevalence of relapsing cases of TB
Downloads
Metrics
References
Banu S, Rahman MT, Ahmed S, Khatun R, Ferdous SS, Hosen B,
et al. Multidrug-resistant tuberculosis in Bangladesh: results
from a sentinel surveillance system. Int J Tuberc Lung Dis 2017;
(1): 12-17. https://doi.org/10.5588/ijtld.16.0384.
Saldanha, N., Runwal, K., Ghanekar, C. High prevalence of
multi drug resistant tuberculosis in people living with HIV in
Western India. BMC Infect Dis 2019; 19: 391.
https://doi.org/10.1186/s12879-019-4042-z.
Akhtar AM, Arif MA, Kanwal S, Majeed S. Prevalence and drug
resistance pattern of MDR TB in retreatment cases of Punjab,
Pakistan. J Pak Med Assoc 2016(8): 989-993.
Ali S, Khan MT, Khan AS, Mohammad N, Khan MM, Ahmad S,
et al. Prevalence of Multi-Drug Resistant Mycobacterium
tuberculosis in Khyber Pakhtunkhwa - A High Tuberculosis
Endemic Area of Pakistan. Pol J Microbiol 2020; 69(2): 1–5.
https://doi.org/10.33073/pjm-2020-005.
Mandatory notification of Tuberculosis Patients. [Internet]. 2020.
Available at: https://ntp.gov.pk/wpcontent/uploads/2020/11/Notification-for-Mandatory-TBcase.jpg. [Accessed on November 12, 2020].
Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug
resistant tuberculosis in Europe: a systematic review. Thorax
;61(2):158-163. https://doi.org/10.1136/thx.2005.045963.
Jamal Y, Jamal A, Ali A, Malik M, Kamran S, Alamgir W. et al.
Resistance patterns in patients of drug resistant pulmonary
tuberculosis. Pak Armed Forces Med J 2019; 69(5): 1077-1082.
Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, MartínCasabona N, et al. Worldwide emergence of extensively drugresistant tuberculosis. Emerg Infect Dis 2007; 13(3): 380-387.
https://doi.org/10.3201/eid1303.061400.
Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, et
al. Prevalence of multidrug-resistant tuberculosis among
category II pulmonary tuberculosis patients. Indian J Med Res
; 133(3): 312-315.
Shao Y, Yang D, Xu W, Lu W, Song H, Dai Y, et al.
Epidemiology of anti-tuberculosis drug resistance in a chinese
population: current situation and challenges ahead. BMC Public
Health 2011; 11(1): 110.
https://doi.org/10.1186/1471-2458-11-110.
Hasan R, Jabeen K, Mehraj V, Zafar F, Malik F, Hassan Q, et al.
Trends in Mycobacterium tuberculosis resistance, Pakistan,
-2007. Int J Infect Dis 2009; 13(6): e377-382.
https://doi.org/10.1016/j.ijid.2009.01.008.
He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, et al.
Prevalence of tuberculosis drug resistance in 10 provinces of
China. BMC Infect Dis 2008; 8(1): 166.
https://doi.org/10.1186/1471-2334-8-166.
Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D.
Treatment of isoniazid-resistant tuberculosis with first-line
drugs: a systematic review and meta-analysis. Lancet Infect Dis
; 17(2): 223-234.
https://doi.org/10.1016/s1473-3099(16)30407-8.
Jenkins HE, Zignol M, Cohen T. Quantifying the burden and
trends of isoniazid resistant tuberculosis, 1994-2009. PloS One
; 6(7): e22927.
https://doi.org/10.1371/journal.pone.0022927.
Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis
R, et al. Multidrug- and extensively drug-resistant tuberculosis,
Germany. Emerg Infect Dis 2008; 14(11): 1700–1706.
https://doi.org/10.3201%2Feid1411.080729.
Zhang Z, Lu J, Wang Y, Pang Y, Zhao Y. Prevalence and
molecular characterization of fluoroquinolone-resistant
Mycobacterium tuberculosis isolates in China. Antimicrob
Agents Chemother 2014; 58(1): 364-349.
https://doi.org/10.1128/AAC.01228-13.
Agrawal D, Udwadia ZF, Rodriguez C, Mehta A. Increasing
incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13(1): 79-83.
Long R, Chong H, Hoeppner V, Shanmuganathan H,
Kowalewska-Grochowska K, Shandro C, et al. Empirical
Treatment of Community-Acquired Pneumonia and the
Development of Fluoroquinolone-Resistant Tuberculosis. Clin
Infect Dis 2009; 48(10): 1354-1360.
https://doi.org/10.1086/598196.
Gao JT, Xie L, Ma LP, Shu W, Zhang LJ, Ning YJ, et al.
Prolonged use of bedaquiline in two patients with pulmonary
extensively drug-resistant tuberculosis: Two case reports. World
J Clin Cases 2021; 9(10): 2326-2333.
https://doi.org/10.12998/wjcc.v9.i10.2326.
Matteelli A, Roggi A, Carvalho AC. Extensively drug-resistant
tuberculosis: epidemiology and management. Clin Epidemiol
; 6: 111-118. https://doi.org/10.2147/CLEP.S35839
Downloads
Published
How to Cite
Issue
Section
